© 2018 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Imbruvica-based treatment may also work better than intensive chemotherapy for younger patients.
Customized cell therapy plus Imbruvica leads to high response rate.
Venclexta plus Gazyva reduces risk of disease progression or death.
INVAC-1 vaccine targets the telomerase enzyme involved in cancer cell growth.
Duvelisib granted regular approval for chronic lymphocytic leukemia and accelerated approval for follicular lymphoma.
The study also demonstrates the need to go beyond genomic DNA analyses in cancer diagnostics.
Approval was based on improves progression-free survival in the MURANO trial.
“There’s nothing that we can’t face together. We’ll never walk alone.”
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
